Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.59 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.49 |
| ▸ | VNN1 | O95497 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.46 |
| ▸ | HPGDS | O60760 | 2/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13876493 | 0.91 | EPHX2 (0.59) | EPHX2EGLN1VNN1P2RX7HPGDS | |
| SCHEMBL13876779 | 0.86 | EPHX2 (0.59) | EPHX2EGLN1VNN1P2RX7HPGDS | |
| SCHEMBL13876337 | 0.84 | EPHX2 (0.60) | EPHX2EGLN1P2RX7HPGDS | |
| SCHEMBL13876316 | 0.84 | EPHX2 (0.58) | EPHX2EGLN1VNN1P2RX7HPGDS | |
| SCHEMBL13876499 | 0.83 | HPGDS (0.59) | EPHX2EGLN1VNN1P2RX7HPGDS | |
| SCHEMBL13876780 | 0.83 | EPHX2 (0.57) | EPHX2EGLN1VNN1P2RX7ALDH1A1 | |
| SCHEMBL13876320 | 0.83 | EPHX2 (0.61) | EPHX2EGLN1P2RX7HPGDS | |
| SCHEMBL13876775 | 0.82 | SCN2A (0.58) | EPHX2EGLN1VNN1P2RX7SMN1; SMN2 | |
| SCHEMBL13876514 | 0.81 | EPHX2 (0.60) | EPHX2HPGDSCASP6 | |
| SCHEMBL13876551 | 0.81 | SMN1; SMN2 (0.49) | EPHX2HPGDSSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| WO-2007098352-A2 | SUBSTITUTED PYRIDINEAMIDE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885EGLN1 198/4885VNN1 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.